slides · global inventory
27 Cost Of Inaction
Loop collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 31,900
Current window 20,191-20,220
Pages 1,064
Rows per page 30
Loop
20,191-20,220 of 31,900
03
Uses a rhetorical question to frame the company's value proposition as a paradigm shift.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
04
Uses a process diagram to illustrate the iterative, inefficient nature of traditional drug discovery.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
05
Uses a visual comparison between small molecule and biologic data availability to frame the problem.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
09
Aeglea BioTherapeutics | Investor Presentation Deck | 56 slidesAeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Golden Circle1 hit
10
The chart compares Cyno Half-Life vs Human Half-Life, showing YTE mAbs outperforming WT mAbs.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Golden Circle1 hit
11
The slide uses a 'before-after' logic to justify the combination strategy.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Golden Circle1 hit
12
Uses a Venn diagram to show target overlap and a bar chart to show clinical efficacy improvement.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Golden Circle1 hit
07
Includes a disclaimer regarding the separation of the oncology business and a footnote about non-GAAP reconciliation.Alkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Key Performance Indicator OverviewLoop · Cost Of Inaction1 hit
08
Alkermes | Results Presentation Deck | 17 slidesAlkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Key Performance Indicator OverviewLoop · Cost Of Inaction1 hit
09
The chart illustrates revenue diversification across four products: VIVITROL, ARISTADA, VUMERITY, and LYBALVI.Alkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Key Performance Indicator OverviewLoop · Cost Of Inaction1 hit
10
The chart displays both weekly data and a 4-week rolling average.Alkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Key Performance Indicator OverviewLoop · Cost Of Inaction1 hit
11
Alkermes | Results Presentation Deck | 17 slidesAlkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Key Performance Indicator OverviewLoop · Cost Of Inaction1 hit
06
The slide uses a spiral/funnel-like diagram to illustrate the compounding nature of patient challenges.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
29
The slide uses a three-column layout to categorize decarbonization efforts into specific scopes and programs.AstraZeneca | Results Presentation Deck | 44 slides · AstraZeneca
Conference presentation Investor relations Beat · ActionLoop · Cost Of Inaction1 hit
30
The slide uses a grid layout to present clinical trial assets on the left and corporate KPIs on the right.AstraZeneca | Results Presentation Deck | 44 slides · AstraZeneca
Conference presentation Investor relations Beat · ActionLoop · Cost Of Inaction1 hit
31
Slide 31 of a presentation deck.AstraZeneca | Results Presentation Deck | 44 slides · AstraZeneca
Conference presentation Investor relations Beat · ActionLoop · Cost Of Inaction1 hit
32
The slide features headshots and titles for 9 executives.AstraZeneca | Results Presentation Deck | 44 slides · AstraZeneca
Conference presentation Investor relations Beat · ActionLoop · Cost Of Inaction1 hit
11
Central Pacific Financial | Results Presentation Deck | 19 slidesCentral Pacific Financial | Results Presentation Deck | 19 slides · Central Pacific Financial
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
08
The slide uses a comparison framework to contrast existing treatments for other conditions with the lack of treatments for FSAD.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
09
This slide outlines regulatory requirements for clinical trial design, including placebo run-in periods, patient population definition, PRO instruments, and primary endpoints.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
10
Dare Bioscience | Investor Presentation Deck | 27 slidesDare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
11
Includes a visual comparison indicating FSAD is not equal to HSDD.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
12
Uses medical diagnostic criteria (DSM) to frame the business opportunity by analogy.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
13
The slide uses a bulleted list structure to categorize the patient experience into physical symptoms, motivations, emotional impact, and psychological concerns.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
08
The slide uses a three-column layout to summarize strategic pillars. The middle column uses an 'In/Out' arrow diagram to illustrate portfolio changes.Unilever | Investor Conference Presentation Deck | 32 slides · Unilever
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
09
The slide uses a three-column layout to show growth trends across three key investment areas.Unilever | Investor Conference Presentation Deck | 32 slides · Unilever
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
14
Uses a 'Misconception vs. Reality' framing to position the company's focus.VinFast | Investor Presentation Deck | 42 slides · VinFast
Pitch deck Investor relations Beat · ProblemLoop · Golden Circle1 hit
15
VinFast | Investor Presentation Deck | 42 slidesVinFast | Investor Presentation Deck | 42 slides · VinFast
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
12
The slide uses a bubble/Venn-style diagram to show market scope and a bar chart for TAM growth.Vivid Seats | Investor Presentation Deck | 24 slides · Vivid Seats
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
13
The slide uses a logo-grid approach to demonstrate market breadth across three primary categories.Vivid Seats | Investor Presentation Deck | 24 slides · Vivid Seats
Pitch deck Investor relations Loop · Cost Of Inaction1 hit